Online citations, reference lists, and bibliographies.

Hexaminolevulinate: A Profile Of Its Use With Blue-light Cystoscopy In The Diagnosis Of Bladder Cancer

Katherine A. Lyseng-Williamson
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Hexaminolevulinate [Cysview® (USA); Hexvix® (EU)], an ester derivative of 5-aminolevulinate, is a valuable option for the diagnosis of bladder cancer when used in conjunction with blue-light (BL) cystoscopy. In clinical trials, the addition of hexaminolevulinate-guided BL cystoscopy to white-light (WL) cystoscopy was generally better at detecting non-muscle-invasive bladder cancer lesions than WL cystoscopy alone, as assessed by a number of endpoints (e.g. increased number and rate of lesion detection), leading to increased rates of complete treatment decisions. Add-on hexaminolevulinate-guided BL cystoscopy reduced tumour recurrence rates relative to WL cystoscopy alone in follow-up studies and, although further studies are needed, may potentially improve survival-related outcomes. Hexaminolevulinate is generally very well tolerated when used to guide BL cystoscopy, with the most common adverse events (i.e. haematuria, dysuria, pain and bladder spasm) being expected as a consequence of the resection procedure.
This paper references
10.3390/molecules16054140
Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Małgorzata Wachowska (2011)
10.1111/bju.12216
Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?
Kathie Alexina Wong (2013)
10.1111/j.1464-410X.2011.10374.x
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Bogdan Florin Geavlete (2012)
10.1038/sj.bjc.6690338
Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study
Norbert Lange (1999)
10.1007/s11934-017-0685-8
The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer
Eugene J. Pietzak (2017)
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
Susan S. Garfield (2013)
10.1016/j.juro.2012.03.127
New optical imaging technologies for bladder cancer: considerations and perspectives.
Jen‐Jane Liu (2012)
10.1016/J.ACUROE.2011.03.006
Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group
Juan Pablo Burgués (2011)
10.1111/bju.13020
Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Juan Palou (2015)
10.5489/cuaj.4568
Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Zachary Klaassen (2017)
10.1186/s12885-015-1522-4
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
Max Yan (2015)
10.1007/s00345-016-1877-4
Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011
Matthias May (2016)
10.1016/j.jnci.2016.03.002
Reducing understaging of bladder cancer with the aid of photodynamic cystoscopy.
Konstantinos Sfetsas (2016)
10.1016/j.juro.2016.09.076
Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma
Giulia I Lane (2017)
10.1111/bju.12752
NICE guidelines on Prostate Cancer Active Surveillance: is UK practice leading the world?
Edward H Streeter (2015)
10.1038/nrurol.2014.245
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Siamak Daneshmand (2014)
10.1016/j.juro.2010.06.148
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Arnulf Stenzl (2010)
FLUORESCENCE CYSTOSCOPY WITH HEXAMINOLEVULINATE IN DIAGNOSIS AND FOLLOW UP OF BLADDER CANCER: FIVE-YEARS EXPERIENCE
Francesco Porpiglia (2013)
10.2165/00126839-200607030-00005
An Open Pharmacokinetic Study of Hexylaminolevulinate-Induced Photodiagnosis after Intravesical Administration
Sabine Collaud (2006)
10.1097/01.ju.0000060782.52358.04
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.
Patrice Jichlinski (2003)
10.1111/j.1464-410X.2011.10090.x
Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Gregers Gautier Hermann (2011)
10.3233/BLC-160060
Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer
Georgios Gakis (2016)
10.1016/J.AFJU.2014.04.005
Photodynamic diagnosis of bladder cancer:Initial experience of a single UK centre
S O Osaghae (2014)
10.1007/s00345-016-1925-0
Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III
Thorsten Bach (2016)
10.1016/j.juro.2007.03.028
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Yves Fradet (2007)
10.1016/J.ACURO.2011.03.003
Diagnóstico fotodinámico con hexaminolevulinato en el cáncer vesical no músculo invasivo: experiencia del grupo BLUE
Jordi Prió Burgués (2011)
10.1177/1756287213510590
Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer
Puck Oude Elferink (2014)
10.1016/j.eururo.2004.10.025
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
Wolfgang Loidl (2005)
10.1016/j.urology.2010.02.067
HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
Bogdan Florin Geavlete (2010)
10.3109/00365599.2011.637954
Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies
Gregers Gautier Hermann (2012)
10.1016/j.urolonc.2017.06.002
Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient?
Maria Apfelbeck (2017)
10.1007/s11255-013-0603-z
Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial
Pavlos Gkritsios (2013)
10.1016/j.juro.2017.03.075
BLUE LIGHT FLEXIBLE CYSTOSCOPY (BLFC) WITH HEXAMINOLEVULINATE (HAL) AND WHITE LIGHT FLEXIBLE CYSTOSCOPY: A PROSPECTIVE, COMPARATIVE, WITHIN‐PATIENT CONTROLLED MULTI‐CENTER PHASE 3 STUDY IN THE DETECTION OF BLADDER CANCER DURING SURVEILLANCE: PPTLBA‐02
Siamak Daneshmand (2017)
10.1016/S0022-5347(05)68625-9
Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach.
Amparo Pons Martí (1999)
10.1016/j.urolonc.2010.09.009
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder.
Seth P. Lerner (2012)
10.1016/J.JURO.2013.02.2633
1279 FOUR-YEAR NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE RATES–A PROSPECTIVE, RANDOMIZED COMPARISON BETWEEN HEXAMINOLEVULINATE BLUE LIGHT AND STANDARD WHITE LIGHT CYSTOSCOPY
Bogdan Florin Geavlete (2013)
10.1016/S1569-9056(13)61075-1
A COMPARISON OF HEXAMINOLAEVULINATE (HEXVIX®) FLU- ORESCENCE CYSTOSCOPY AND WHITE LIGHT CISTOSCOPY FOR THE DETECTION OF BLADDER CANCER: RESULTS OF THE HERO OBSERVATIONAL STUDY
Alberto Lapini (2012)
10.1007/s00345-015-1485-8
Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy
Georgios Gakis (2015)
10.1016/j.eururo.2016.05.041
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Marko Babjuk (2017)
10.1097/MOU.0B013E3283501869
Fluorescence guidance in urologic surgery.
Nynke S. van den Berg (2012)
10.1089/END.2016.0804
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
PagliaruloVincenzo (2017)
10.1016/j.eururo.2016.11.030
Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
Harry W. Herr (2017)
10.1016/J.JURO.2016.02.742
MP23-20 BLUE LIGHT CYSTOSCOPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER: RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY
Soroush T. Bazargani (2016)
10.1016/J.JVAL.2013.08.493
Cost-Effectiveness of the Optical Imaging Agent Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer
Florence Marteau (2013)
10.1016/J.PUROL.2011.09.012
Intérêt de la vidéocystoscopie souple en lumière bleue (+Hexvix®) en consultation pour le diagnostic des tumeurs de vessie
J. Bertrand (2012)
10.3233/BLC-160048
The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis
Ashish M. Kamat (2016)
10.1016/j.juro.2016.10.061
Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta‐Analysis
Roger Chou (2017)
10.1016/j.juro.2012.03.007
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
Herbert Barton Grossman (2012)
10.1097/01.ju.0000075054.38441.2d
Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
Alexandre Marti (2003)
10.1016/j.juro.2007.03.034
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Herbert Barton Grossman (2007)
10.1177/0091270006286849
Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers.
Bernie Klem (2006)
10.1097/01.ju.0000100480.70769.0e
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Jörg Schmidbauer (2004)
10.1007/s00464-012-2387-0
A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study
Alberto Lapini (2012)
10.1097/01.ju.0000169257.19841.2a
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Dieter Jocham (2005)
10.1177/1756287215603274
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder
Savino M. Di Stasi (2015)
10.1016/j.urology.2012.03.067
Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
Theocharis Karaolides (2012)
10.1016/j.eururo.2013.03.059
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Maximilian Burger (2013)
10.1016/j.eururo.2004.09.017
Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study.
Johannes Alfred Witjes (2005)
10.1016/j.urology.2015.04.015
Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Paramananthan Mariappan (2015)
10.1016/j.urology.2014.03.006
Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
Johannes Alfred Witjes (2014)
10.1016/j.juro.2016.06.049
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
Sam S. Chang (2016)
10.1186/s12885-015-1571-8
A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging
Joo Yong Lee (2015)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1016/J.JURO.2014.02.857
MP22-09 FLEXIBLE PHOTODYNAMIC DIAGNOSIS OF THE BLADDER – READY FOR THE OUTPATIENT SETTING?
Alexander H. Karl (2014)



Semantic Scholar Logo Some data provided by SemanticScholar